Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study

Dongming Zhang, Mengzhao Wang, Fangfang Shen et al.|Translational Lung Cancer Research|2023

Cited by 20